All Videos

Christopher Bunick, MD, PhD, discussed new data suggesting emergency departments continue to rely on outdated therapies for pediatric atopic dermatitis flares despite evolving dermatology guidelines.

Konika Patel Schallen, MD, discussed how nanofractional laser treatments may support regenerative skin health beyond cosmetic improvement and outlined the next research priorities in a recent Dermatology Times interview

Eugene R. Semenov, M.D., M.A., F.A.A.D, discussed AI models that combine pathology and clinical data to better predict recurrence in early-stage melanoma

Konika Patel Schallen, MD, senior vice president and medical director of global clinical operations at Candela Medical, discussed epigenetic changes linked to laser skin resurfacing in a recent Dermatology Times interview.

Christopher Bunick, MD, PhD, discussed the scientific advances still needed before precision medicine can guide individualized therapy selection in atopic dermatitis during a recent Dermatology Times interview.

Kathleen Suozzi, MD, details how she debunks sunscreen myths, explains absorption and SPF, urges year‑round UV habits, and previews new filter bemotrizinol, when counseling her own patients.

In “The Safety of Advanced Topical Therapies in Inflammatory Dermatoses,” our panel explores the consensus statements evaluating the short- and long-term safety of advanced targeted topical therapies for inflammatory skin diseases. The expert faculty review the growing body of clinical trial evidence supporting several nonsteroidal topical treatments, including roflumilast, tapinarof, ruxolitinib, crisaborole, and delgocitinib, and discuss how these therapies have expanded treatment options across multiple inflammatory dermatoses.

In this episode, “Understanding Corticosteroid-Related Medical-Legal Risks in Inflammatory Dermatoses,” the expert faculty explore the consensus statement addressing the medical-legal considerations associated with corticosteroid prescribing and the importance of responsible corticosteroid stewardship in clinical practice. The panel discusses how growing awareness of corticosteroid-related adverse events has implications not only for patient safety, but also for clinician accountability and risk management.

Peter Lio, MD, discussed how stress, sleep disruption, and patient-centered communication can influence pediatric atopic dermatitis management during a recent Skin and Psych podcast interview.

Kathleen Suozzi, MD, explains how UV damage shows up, why actinic keratoses matter, and which field therapies and lasers help cut skin cancer risk.

In this episode titled "Setting Expectations: Treatment Timelines, Adherence, and Monitoring in Vitiligo," moderator Nada Elbuluk, MD, MSc, FAAD and panelist Susan Taylor, MD, FAAD discuss realistic repigmentation timelines, adherence strategies, and how to keep patients motivated throughout the long treatment journey.

In this episode titled "Shared Decision-Making and the Vitiligo Treatment Landscape," moderator Nada Elbuluk, MD, MSc, FAAD and panelist Susan Taylor, MD, FAAD discuss the importance of individualized, goal-directed decision-making in vitiligo treatment and provide an overview of available therapeutic options.

Black Girl Sunscreen founder Shontay Lundy debunks SPF myths for skin of color, urging education, representation, and teamwork for healthier skin.

See how gene expression profiling bridges guideline gaps in high‑risk skin SCC, guiding radiation, follow‑up, and precision treatment decisions.

Konika Patel Schallen, MD, discussed new findings showing the Nordlys 1940 nm non-ablative fractional laser may reverse epigenetic markers of skin aging in a recent Dermatology Times interview.

Gene expression profiling refines cutaneous SCC risk beyond guidelines, influencing surveillance, radiation decisions, and neoadjuvant immunotherapy.

Roman Bronfenbrener, MD, discussed changing exit strategies, private equity, and why peer support may be one of the most valuable resources for independent dermatologists.

Philip J. Mease, MD, reviews guselkumab's mechanism of action and its expanded FDA-approved indication for psoriatic arthritis joint damage inhibition.

Bradley Burnam, founder and CEO of Turn Therapeutics, discussed GX-03's encouraging interim safety profile, regulatory strategy, and next steps in clinical development.

Black Girl Sunscreen CEO and founder reveals why daily SPF matters for deeper skin tones, tackling white cast, education gaps, and inclusive sun care testing.

Christopher Bunick, MD, PhD, shared practical guidance on sun protection, swimming, and preserving the skin barrier in patients with atopic dermatitis.

Bradley Burnam, founder and CEO of Turn Therapeutics, explains the statistical rationale behind GX-03's phase 2 end point strategy and patient stratification.

Philip J. Mease, MD, explains the rationale for early biologic treatment in psoriatic arthritis following guselkumab's FDA label expansion to address structural joint damage.

Roman Bronfenbrener, MD, discussed how dermatologists are using AI to streamline documentation, summarize patient records, support clinical decision-making, and improve practice operations.

This episode, titled “Moving Beyond Long-Term Topical Corticosteroid Use in Inflammatory Dermatoses,” features panelists discussing the evolving role of topical corticosteroids in the management of chronic inflammatory skin diseases. Building on the consensus statement that topical corticosteroids should not be routinely prescribed for long-term use in chronic conditions, the expert faculty examine the distinction between acute flare management and long-term disease control.

In “Reducing Treatment Burden in Inflammatory Dermatoses,” our panel explores the practical challenges associated with managing chronic inflammatory skin diseases using multiple topical corticosteroids. Building on the consensus statement that the use of different corticosteroids for different body areas can create significant burden for patients, the expert faculty discuss how increasingly complex treatment regimens can negatively impact adherence, disease control, and the overall patient experience.

Bradley Burnam, founder and CEO of Turn Therapeutics, discussed interim phase 2 trial findings showing GX-03 efficacy across a broader range of EASI severity scores in atopic dermatitis.

The panel explores how to differentiate CSU from chronic inducible urticaria and acute urticaria, including the potential for overlap between subtypes.

In this episode titled "Active vs. Stable Vitiligo: Defining Disease Activity and Psychosocial Burden," moderator Nada Elbuluk, MD, MSc, FAAD and panelist Susan Taylor, MD, FAAD address the clinical distinction between active and stable vitiligo, as well as the significant psychological impact of the disease.

The panel examines how to distinguish CSU from other urticaria subtypes, how to approach angioedema, and how limited—or expansive—the diagnostic workup should be.